Semin Liver Dis
DOI: 10.1055/s-0041-1723030
Review Article

Assessing Toxicity in Drug Trials in Liver Disease

Morris Sherman
1  Research Administration, University Health Network, Toronto, Canada
› Author Affiliations

Abstract

Since the early trials in viral hepatitis, more and more new drugs are being tested for use in various liver diseases. Since drug hepatotoxicity is a major cause of drugs under investigation not making it to market, the assessment of drug-induced liver injury in clinical trials of new drugs is crucial. This review will focus on the systems that are used to assess drug-induced liver injury in clinical trials and will discuss how some of these criteria are inappropriate or inaccurate in this function together with suggestions for improvement.



Publication History

Publication Date:
08 March 2021 (online)

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA